Skip to menu Skip to content Skip to footer
Associate Professor Joy Wolfram
Associate Professor

Joy Wolfram

Email: 

Overview

Background

Associate Professor Joy Wolfram leads an extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of medicines directly to the clinic to alter the trajectory of life-threatening diseases, improve patient outcomes, and prolong healthy lifespans. Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, Australia (#41 in Best Global Universities, U.S. News & World Report).

MISSION

1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer

2) Save lives by manufacturing at scale, by delivering national manufacturing innovation and a skilled workforce

3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine

Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional pharmaceuticals due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading of extracellular vesicles to develop therapeutics.

FOCUS AREAS

1) Developing improved methods for extracellular vesicle isolation from human biofluids

2) Designing hybrid drug delivery systems with extracellular vesicle and synthetic components for a ‘best-of-both-worlds’ approach to treat cardiovascular disease and aging kidney disease

3) Understanding the role of extracellular vesicles in cancer immunoevasion and metastasis

The research program has resulted in more than 100 publications in journals, such as, Nature Nanotechnology, Materials Today, and Nature Reviews Materials. These publications have been cited 16,800 times (Google Scholar). The Wolfram Laboratory has collaborated with 160 universities and industry partners across 45 countries (Scopus). The research program has also been featured in more than 100 presentations at scientific meetings, including 80+ invited talks and nine international keynote talks.

Wolfram is actively involved in community outreach and education, including in her previous roles as the Chair of an education and outreach working group of the National Institutes of Health in the United States and the Associate Program Director of the PhD Program in Regenerative Sciences at Mayo Clinic (Best Hospital in the World, Newsweek). As a TED speaker, she strives to bring science to a wide audience.

She has received 40+ awards from nine countries, including the 2016 Amgen Scholars Ten to Watch List (best and brightest up-and-comers in science and medicine across 42 countries), the 2019 Forbes 30 under 30 list in Health Care in the United States/Canada, the 2019 shortlist for the Nature Research Award for Inspiring Science (one of ten worldwide), and the 2021 Finnish Expatriate of the Year (past recipients include Nobel Memorial Prize winners, Millennium Technology Prize winners, and Formula 1 drivers). She is in the top 1% of researchers worldwide in the categories of ‘Biology & Biochemistry’ and ‘Pharmacology & Toxicology' (Essential Science Indicators, 2023) and in the top 0.5% in 'Extracellular Vesicles' (ScholarGPS 5/2024).

Availability

Associate Professor Joy Wolfram is:
Available for supervision
Media expert

Qualifications

  • Bachelor, University of Helsinki*
  • Masters (Coursework), University of Helsinki*
  • Doctor of Philosophy, University of the Chinese Academy of Science
  • Member, Global Young Academy, Global Young Academy
  • Honorary Academic, Houston Methodist Hospital, Houston Methodist Hospital
  • Member, The Swedish Academy of Engineering Sciences in Finland, The Swedish Academy of Engineering Sciences in Finland

Works

Search Professor Joy Wolfram’s works on UQ eSpace

236 works between 2009 and 2025

121 - 140 of 236 works

2019

Journal Article

Extracellular vesicle-based drug delivery systems for cancer treatment

Walker, Sierra, Busatto, Sara, Pham, Anthony, Tian, Ming, Suh, Annie, Carson, Kelsey, Quintero, Astrid, Lafrence, Maria, Malik, Hanna, Santana, Moises X and Wolfram, Joy (2019). Extracellular vesicle-based drug delivery systems for cancer treatment. Theranostics, 9 (26), 8001-8017. doi: 10.7150/thno.37097

Extracellular vesicle-based drug delivery systems for cancer treatment

2019

Journal Article

Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles

Nizzero, Sara, Li, Feng, Zhang, Guodong, Venuta, Alessandro, Borsoi, Carlotta, Mai, Junhua, Shen, Haifa, Wolfram, Joy, Li, Zheng, Blanco, Elvin and Ferrari, Mauro (2019). Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles. Acta Biomaterialia, 97, 501-512. doi: 10.1016/j.actbio.2019.08.002

Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles

2019

Conference Publication

How nanoparticles could change the way we treat cancer

Wolfram, Joy (2019). How nanoparticles could change the way we treat cancer. TED, Global, October 2019.

How nanoparticles could change the way we treat cancer

2019

Journal Article

Adipose-derived cellular and cell-derived regenerative therapies in dermatology and aesthetic rejuvenation

Suh, Annie, Pham, Anthony, Cress, Mikel Jean, Pincelli, Thais, TerKonda, Sarvam P., Bruce, Alison J., Zubair, Abba C., Wolfram, Joy and Shapiro, Shane A. (2019). Adipose-derived cellular and cell-derived regenerative therapies in dermatology and aesthetic rejuvenation. Ageing Research Reviews, 54 100933. doi: 10.1016/j.arr.2019.100933

Adipose-derived cellular and cell-derived regenerative therapies in dermatology and aesthetic rejuvenation

2019

Conference Publication

Education and outreach summary

Wolfram, Joy (2019). Education and outreach summary. Physical Sciences - Oncology Network Annual Meeting, Minneapolis, MN, United States , September 2019.

Education and outreach summary

2019

Journal Article

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine (Nature Nanotechnology, (2019), 14, 7, (629-635), 10.1038/s41565-019-0496-9)

Leong, Hon S., Butler, Kimberly S., Brinker, C. Jeffrey, Azzawi, May, Conlan, Steve, Dufès, Christine, Owen, Andrew, Rannard, Steve, Scott, Chris, Chen, Chunying, Dobrovolskaia, Marina A., Kozlov, Serguei V., Prina-Mello, Adriele, Schmid, Ruth, Wick, Peter, Caputo, Fanny, Boisseau, Patrick, Crist, Rachael M., McNeil, Scott E., Fadeel, Bengt, Tran, Lang, Hansen, Steffen Foss, Hartmann, Nanna B., Clausen, Lauge P. W., Skjolding, Lars M., Baun, Anders, Ågerstrand, Marlene, Gu, Zhen, Lamprou, Dimitrios A. ... Pastore, Chiara (2019). Publisher Correction: On the issue of transparency and reproducibility in nanomedicine (Nature Nanotechnology, (2019), 14, 7, (629-635), 10.1038/s41565-019-0496-9). Nature Nanotechnology, 14 (9), 902-902. doi: 10.1038/s41565-019-0538-3

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine (Nature Nanotechnology, (2019), 14, 7, (629-635), 10.1038/s41565-019-0496-9)

2019

Conference Publication

Diagnostic and therapeutic biogenic nanoparticles

Wolfram, Joy (2019). Diagnostic and therapeutic biogenic nanoparticles. Vall d'Hebron Research Institute Seminar Series, Barcelona, Spain , 10 September 2019.

Diagnostic and therapeutic biogenic nanoparticles

2019

Conference Publication

Extracellular vesicles secreted from braintropic cells display distinct interactions with brain endothelial cells

Busatto, Sara, Walker, Sierra A. and Wolfram, Joy (2019). Extracellular vesicles secreted from braintropic cells display distinct interactions with brain endothelial cells. The First International Society for Extracellular Vesicles and Metastasis Research Society Joint Extracellular Vesicle Conference Focused on Cancer, Nashville, TN, United States, August 2019.

Extracellular vesicles secreted from braintropic cells display distinct interactions with brain endothelial cells

2019

Journal Article

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine (Nature Nanotechnology, (2019), 14, 7, (629-635), 10.1038/s41565-019-0496-9)

Leong, Hon S., Butler, Kimberly S., Brinker, C. Jeffrey, Azzawi, May, Conlan, Steve, Dufès, Christine, Owen, Andrew, Rannard, Steve, Scott, Chris, Chen, Chunying, Dobrovolskaia, Marina A., Kozlov, Serguei V., Prina-Mello, Adriele, Schmid, Ruth, Wick, Peter, Caputo, Fanny, Boisseau, Patrick, Crist, Rachael M., McNeil, Scott E., Fadeel, Bengt, Tran, Lang, Hansen, Steffen Foss, Hartmann, Nanna B., Clausen, Lauge P. W., Skjolding, Lars M., Baun, Anders, Ågerstrand, Marlene, Gu, Zhen, Lamprou, Dimitrios A. ... Pastore, Chiara (2019). Publisher Correction: On the issue of transparency and reproducibility in nanomedicine (Nature Nanotechnology, (2019), 14, 7, (629-635), 10.1038/s41565-019-0496-9). Nature Nanotechnology, 14 (8), 811-811. doi: 10.1038/s41565-019-0523-x

Publisher Correction: On the issue of transparency and reproducibility in nanomedicine (Nature Nanotechnology, (2019), 14, 7, (629-635), 10.1038/s41565-019-0496-9)

2019

Conference Publication

Open science success in community outreach

Walker, Sierra A., Pham, Anthony, Busatto, Sara and Wolfram, Joy (2019). Open science success in community outreach. Sage Assembly: Open Science and the Role of Common Evidence, Seattle, WA, United States , July 2019.

Open science success in community outreach

2019

Journal Article

On the issue of transparency and reproducibility in nanomedicine

Leong, Hon S., Butler, Kimberly S., Brinker, C. Jeffrey, Azzawi, May, Conlan, Steve, Dufés, Christine, Owen, Andrew, Rannard, Steve, Scott, Chris, Chen, Chunying, Dobrovolskaia, Marina A., Kozlov, Serguei V., Prina-Mello, Adriele, Schmid, Ruth, Wick, Peter, Caputo, Fanny, Boisseau, Patrick, Crist, Rachael M., McNeil, Scott E., Fadeel, Bengt, Tran, Lang, Hansen, Steffen Foss, Hartmann, Nanna B., Clausen, Lauge P. W., Skjolding, Lars M., Baun, Anders, Ågerstrand, Marlene, Gu, Zhen, Lamprou, Dimitrios A. ... Pastore, Chiara (2019). On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 14 (7), 629-635. doi: 10.1038/s41565-019-0496-9

On the issue of transparency and reproducibility in nanomedicine

2019

Journal Article

Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles

Busatto, Sara, Pham, Anthony, Suh, Annie, Shapiro, Shane and Wolfram, Joy (2019). Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles. Biomedical Microdevices, 21 (2) 46, 46. doi: 10.1007/s10544-019-0396-7

Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles

2019

Conference Publication

Education and outreach unit

Wolfram, Joy (2019). Education and outreach unit. National Cancer Institute Physical Sciences-Oncology Network Site Visit, Houston, TX, United States , May 2019.

Education and outreach unit

2019

Conference Publication

Adipose extracellular vesicles derived from female lipoaspirate inhibit viral myocarditis: potential new therapy

Di Florio, Damian, Bruno, Katelyn, Hill, A.R., Tian, Ming, Wolfram, Joy and Fairweather, DeLisa (2019). Adipose extracellular vesicles derived from female lipoaspirate inhibit viral myocarditis: potential new therapy. Organization for the Study of Sex Differences (OSSD) Annual Meeting, Washington, DC, United States , May 2019.

Adipose extracellular vesicles derived from female lipoaspirate inhibit viral myocarditis: potential new therapy

2019

Conference Publication

Extracellular vesicles as therapeutic and diagnostic agents

Wolfram, Joy (2019). Extracellular vesicles as therapeutic and diagnostic agents. Center for Immunotherapeutic Transport Oncophysics Seminar Series, Houston, TX USA, April 2019.

Extracellular vesicles as therapeutic and diagnostic agents

2019

Conference Publication

Bringing life science innovation to the clinic

Wolfram, Joy (2019). Bringing life science innovation to the clinic. Enventure, Houston, TX USA, April 2019.

Bringing life science innovation to the clinic

2019

Conference Publication

Nanotherapeutics for cancer and regenerative medicine

Wolfram, Joy (2019). Nanotherapeutics for cancer and regenerative medicine. University of Oulu Biocenter Oulu Day, Oulu, Finland, April 2019.

Nanotherapeutics for cancer and regenerative medicine

2019

Conference Publication

Extracellular vesicles in breast cancer

Wolfram, Joy (2019). Extracellular vesicles in breast cancer. Mayo Clinic Breast Cancer Retreat, Rochester, MN USA, April 2019.

Extracellular vesicles in breast cancer

2019

Journal Article

Clinical cancer nanomedicine

Wolfram, Joy and Ferrari, Mauro (2019). Clinical cancer nanomedicine. Nano Today, 25, 85-98. doi: 10.1016/j.nantod.2019.02.005

Clinical cancer nanomedicine

2019

Conference Publication

Three emerging concepts in clinical nanomedicine

Wolfram, Joy (2019). Three emerging concepts in clinical nanomedicine. Harvard Medical School Initiative for RNA Medicine Seminar Series, Boston, MA, United States , March 2019.

Three emerging concepts in clinical nanomedicine

Funding

Current funding

  • 2025 - 2028
    Deciphering the role of muscle-derived extracellular vesicles in ALS pathology
    Cure for MND Foundation - Discovery Research Grants
    Open grant
  • 2025 - 2028
    Extracellular vesicle therapeutics for cardiac surgery-induced inflammation
    National Heart Foundation Future Leader Fellowship
    Open grant
  • 2024 - 2027
    Treating breast cancer metastasis by targeting immunosuppressive extracellular vesicles
    National Breast Cancer Foundation
    Open grant
  • 2023 - 2026
    Extracellular vesicle-based senotherapeutics for aging diabetic kidney disease (NIH grant administered by Mayo Clinic)
    Mayo Clinic
    Open grant
  • 2023 - 2025
    Studying the basis of and developing new therapies to treat heart disease
    IPF Healthy - Medical Research
    Open grant
  • 2023 - 2026
    Personalising Innate-immunotherapy for Superior Treatment Outcomes with Large anticancer applicability (PISTOL)
    NHMRC MRFF EMCR - Early to Mid-Career Researchers
    Open grant

Past funding

  • 2024
    Monolithic chromatography for improved isolation of plasma-derived extracellular vesicles - Phase 2
    SARTORIUS STEDIM AUSTRALIA PTY. LTD
    Open grant
  • 2024
    Australia-United States Breast Cancer Consumer Workshop in Queensland
    Health Translation Queensland
    Open grant
  • 2023 - 2024
    CIMmultus Chromatographic Monolithic Columns for Isolation of Extracellular Vesicles from Plasma - Phase 1
    SARTORIUS STEDIM AUSTRALIA PTY. LTD
    Open grant
  • 2022 - 2024
    Going viral with extracellular vesicles: virus biology informs next-generation EV therapeutics
    Ionis Pharmaceuticals - Ion-ARPA Program Operation Payload Delivery
    Open grant

Supervision

Availability

Associate Professor Joy Wolfram is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Developing extracellular vesicle therapeutics for cardiovascular inflammation

    Every 12 minutes, one Australian dies of cardiovascular disease, accounting for 40,000+ annual deaths at a cost of $11.8B/year. Want to help us develop treatments for cardiovascular disease, the leading cause of death worldwide?

    Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for inflammatory cardiovascular disease.

    Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of cardiovascular disease, improve patient outcomes, and prolong healthy lifespan.

    This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat cardiovascular disease.

    LONG-TERM GOALS

    1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat cardiovascular inflammation.

    2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.

    3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.

  • Developing extracellular vesicle therapeutics for aging kidney disease

    In the upcoming decades, health care systems are predicted to collapse due to aging-associated diseases. Chronickidney disease is on the rise in the aging population and currently affects an estimated 1.7M Australians at a cost of $1.9B annually.

    Want to help us develop treatments for aging kidney disease? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for aging kidney disease.

    Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of aging diabetic kidney disease, improve patient outcomes, and prolong healthy lifespan.

    This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat aging kidney disease.

    LONG-TERM GOALS

    1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat aging kidney disease.

    2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.

    3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.

  • Understanding the contribution of extracellular vesicles in breast cancer immunoevasion

    The deadliest breast cancer is the triple-negative subtype, which has few treatment options. New treatments are urgently needed to prevent deaths and improve the quality of life for the 3,000 Australians who are diagnosed with triple-negative breast cancer every year.

    Want to help us develop treatments for deadly breast cancer? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle-informed understanding and therapeutics for breast cancer.

    The immune system is known to play a critical role in detecting and eliminating breast cancer cells and the Wolfram Laboratory has shown that triple-negative breast cancer cells release extracellular vesicles with harmful biomolecules that help the cancer cells avoid detection and destruction by the immune system. The project involves assessing how these extracellular vesicles affect the ability of immune cells to destroy breast cancer cells. The project also involves the development of new treatment options for breast cancer, including engineering natural killer cells to be resistant to extracellular vesicle-mediated suppression.

    The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and targeting of extracellular vesicles to alter the trajectory of breast cancer, improve patient outcomes, and prolong healthy lifespan.

    LONG-TERM GOALS

    1) Uncover the mechanisms by which breast cancer extracellular vesicles suppress the immune system.

    2) Develop a new paradigm of therapeutics (using engineered immune cells) to treat triple negative breast cancer.

    3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.

Supervision history

Current supervision

  • Doctor Philosophy

    The extracellular vesicle bio-nano interactome in cancer metastasis.

    Principal Advisor

  • Doctor Philosophy

    Extracellular vesicle-based senotherapeutics for aging diabetic kidney disease

    Principal Advisor

    Other advisors: Dr Zhengni Liu

  • Doctor Philosophy

    Mutation Targeting Therapy for Cancer with dCas9

    Principal Advisor

  • Doctor Philosophy

    Engineered Extracellular Vesicles for Synergistic Myocardial Infarction Therapy

    Principal Advisor

  • Doctor Philosophy

    Maximising the success of cancer immunotherapy by preventing extracellular vesicle hijacking of the immune system

    Principal Advisor

    Other advisors: Dr Allie Lam, Dr Zhengni Liu

Media

Enquiries

Contact Associate Professor Joy Wolfram directly for media enquiries about:

  • Biomanufacturing
  • Bioseparation
  • Biotherapeutics
  • Breast cancer
  • Exosomes
  • Extracellular vesicles
  • Nanomedicine
  • Nanoparticles
  • Regenerative medicine
  • Scientific outreach

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au